Tango Therapeutics
Tango Therapeutics raises $165M Series B at $600M valuation
Tango Therapeutics: Series B Funding Round
Tango Therapeutics has successfully raised $165M in Series B funding, reaching a valuation of $600M.
Company Overview
Cancer therapeutics discovering synthetic lethal drug targets
Funding Details
The Series B round was led by Third Rock Ventures, with participation from BVF Partners, Boxer Capital, Casdin Capital.
Company Information
- Headquarters: 100 Binney Street, Cambridge, MA 02142
- Founded: 2017
- Employees: 120+
- Category: Biotech
Investment
Tango Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Third Rock Ventures: Verified investor in Series B
- BVF Partners: Verified investor in Series B
- Boxer Capital: Verified investor in Series B
- Casdin Capital: Verified investor in Series B
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free